Table 1 Key Model Inputs
Parameter | Value | Source |
|---|---|---|
Initial health distribution: | ||
Normal | 0.00 % | Phase III trial [16] |
Mild | 3.52 % | |
Moderate | 90.55 % | |
Severe | 5.93 % | |
Utility inputs: | ||
Normal | 0.839 | Lloyd et al. [31] |
Mild | 0.787 | |
Moderate | 0.578 | |
Severe | 0.444 | |
Weekly medical costs: | ||
Normal | $4.71 | Derived from Guevara et al. [25], Schedule of Benefit and Fees, OHIP, OCCI |
Mild | $4.76 | |
Moderate | $13.63 | |
Severe | $28.38 | |
Weekly costs associated with productivity losses for parents of children with ADHD (societal perspective): | ||
Normal | $14.60 | Hakkaart-van Roijen et al. [29] Statistics Canada |
Mild | $15.38 | |
Moderate | $60.30 | |
Severe | $125.10 | |
Daily cost of ADHD medication, $CA: | ||
GXR | $3.89 | Quebec’s Medication List |
MAS-XR (Adderall XR®) | $3.24 | |
MPH-CR (Biphentin®) | $1.77 | ODB |
OROS-MPH (Concerta®) | $2.76 | Market shares – Canada |
OROS-MPH (generic) | $1.91 | (except Quebec), IMS Brogan |
LDX (Vyvanse®) | $3.75 | |
Long-acting stimulants - Overall | $2.80 | Weighted average cost |
Percentage of patients taking long-acting stimulants: | ||
GXR | – | Market shares – Canada (except Quebec), IMS Brogan |
MAS-XR (Adderall XR®) | 14.20 % | |
MPH-CR (Biphentin®) | 15.30 % | |
OROS-MPH (Concerta®) | 46.10 % | |
OROS-MPH (generic) | 6.40 % | |
LDX (Vyvanse®) | 18.00 % | |